MedTrace Logo

Adjunctive Bright Light Therapy for Patients With Depression

NCT04633707 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2021-03-23

No results posted yet for this study

Summary

The study would enroll depressed adolescents and adults with bipolar I or II disorder or major depressive disorder who are receiving stable psychiatric medication (excluding patients with hypomania or mania, mixed symptoms, or rapid cycling). Participants would be randomly assigned to treatment with either 1,0000-lux bright white light therapy in the morning or 1,0000-lux bright white light therapy in the afternoon, or \<100-lux dim red placebo light therapy in the afternoon (N=59 for each group). Participants would be treated for 6 weeks. Symptoms would be assessed every two weeks with the 24-items Hamilton Depression Scale, the Young Mania Rating Scale, and the Pittsburgh Sleep Quality Index; salivary melatonin and cortisol concentrations will be also measured.

Conditions

  • Depressive Disorder
  • Light Therapy

Interventions

DEVICE

adjunctive bright white light therapy in the morning

the participants would receive adjunctive bright white light therapy in the morning (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 7:00\~9:00) for 6 weeks.

DEVICE

adjunctive bright white light therapy in the afternoon

the participants would receive adjunctive bright white light therapy in the afternoon (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 12:00\~14:00) for 6 weeks.

DEVICE

adjunctive dim red light therapy in the afternoon

the participants received dim red light therapy (light intensity: \<100lux, color: dark red, duration of each intervention session: 30min, time period: 12:00\~14:00) for 6 weeks.

Sponsors & Collaborators

  • Guangzhou Psychiatric Hospital

    lead OTHER_GOV

Principal Investigators

  • Lin Kangguang, MD;PHD · Guangzhou Psychiatric Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-31
Primary Completion
2022-05-31
Completion
2022-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04633707 on ClinicalTrials.gov